tuneTypical Dose
600 mg daily for proprietary extracts such as Testofen, with other metabolic trials using different seed or extract protocols
Botanical
Fenugreek
Trigonella foenum-graecum
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Glycemic and symptom outcomes are typically assessed over several weeks rather than days.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Fenugreek has modest evidence for glycemic support in type 2 diabetes, but libido and lactation claims are more product specific and much less secure than supplement marketing suggests.
Fenugreek gets marketed for blood sugar control, testosterone, libido, body composition, and milk supply. The strongest human evidence is for modest glycemic support in type 2 diabetes. Beyond that, the literature becomes much less stable. Men’s-health benefits come mostly from proprietary extracts such as Testofen, and galactagogue claims rest on small heterogeneous studies with mixed preparations, even after a newer preterm-mother RCT. A 2026 human safety review also supports mostly mild GI, allergy, and hypoglycemia-risk framing rather than a major toxicity signal. Fenugreek remains a plausible adjunct in a few narrow settings, not a broadly proven metabolic or hormonal supplement.
Fenugreek contains fiber, saponins, and other phytochemicals that may affect postprandial glucose handling, insulin sensitivity, and possibly sex-hormone-related signaling. The mechanistic story is plausible, but the clinical evidence is strongest for metabolic outcomes and much weaker for generic testosterone or libido claims.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Modest improvement in glycemic control in type 2 diabetes
Secondary Outcomes
- Possible product-specific improvement in male sexual-function scores
- Possible but inconsistent increase in breast milk volume
Safety
Contraindications and Interactions
Contraindications
- Pregnancy
- Peanut, chickpea, or fenugreek allergy
- Active hypoglycemia risk or intensive glucose-lowering therapy
Side effects
- Bloating or GI upset
- Diarrhea
- Maple-syrup-like body odor
Interactions
- Antidiabetic medications
- Anticoagulant or antiplatelet strategies
Avoid if
- You are using it as a generic testosterone booster
- You are pregnant without clinician guidance
- You have a relevant legume allergy
Evidence
Study-level References
fg-SRC-001Systematic review and meta-analysis
Sourceopen_in_newGhaffari S, Abbasalizad Farhangi M, Aliasghari F, et al. Therapeutic effect of fenugreek supplementation on type 2 diabetes mellitus. A systematic review and meta-analysis of clinical trials. Rev Endocr Metab Disord. 2024. doi:10.1007/s11154-024-09942-6. PMID:39286181.
Population: Adults with type 2 diabetes mellitus enrolled in clinical trials of fenugreek supplementation.
Dose protocol: Various fenugreek preparations used in type 2 diabetes trials
Key findings: Improved fasting blood glucose and HbA1c in pooled analyses.
Notes: Best current anchor for metabolic framing.
Paper content
This is the strongest current overview for fenugreek's metabolic use case. It supports a modest glycemic benefit in people with type 2 diabetes, but the literature is heterogeneous across preparations and study quality. That makes fenugreek a plausible adjunct for glycemic control, not a replacement for standard diabetes care.
fg-SRC-002Systematic review and meta-analysis
Sourceopen_in_newGhaffari S, Roshanravan N, Tutunchi H, et al. The Effects of Fenugreek on Cardiometabolic Risk Factors in Adults. A systematic review and meta-analysis. Complement Ther Med. 2020;52:102537. doi:10.1016/j.ctim.2020.102537. PMID:32951700.
Population: Adults across 12 controlled clinical trials of fenugreek supplementation.
Dose protocol: Various seed and extract protocols
Key findings: Modest or inconsistent cardiometabolic effects, with possible triglyceride and HDL improvement.
Notes: Useful for tempering overbroad metabolic claims.
Paper content
This broader cardiometabolic meta-analysis is less impressive than the diabetes-specific literature. It suggests possible improvements in triglycerides and HDL-C, while glycemic findings remain heterogeneous. The paper is useful because it keeps fenugreek from being overstated as a robust lipid or broad cardiometabolic supplement.
fg-SRC-003Randomized controlled trial
Sourceopen_in_newRao A, Steels E, Inder WJ, et al. Testofen, a specialised Trigonella foenum-graecum seed extract reduces age-related symptoms of androgen decrease, increases testosterone levels and improves sexual function in healthy aging males in a double-blind randomised clinical study. Aging Male. 2016;19(2):134-142. doi:10.1080/13685538.2015.1135323. PMID:26791805.
Population: Healthy men aged 43 to 70 years with symptoms of androgen decrease.
Dose protocol: 600 mg daily for 12 weeks
Key findings: Improved sexual-function and aging-male-symptom scores with a proprietary extract.
Notes: Product specific and commercially exposed.
Paper content
This trial is the main reason fenugreek still appears in libido and men's-health marketing. It reported better sexual-function and aging-male-symptom scores with a specialized 600 mg extract over 12 weeks. The problem is that these findings are product specific and not consistently reproduced across the broader fenugreek literature, so they support only a narrow, low-confidence libido claim.
fg-SRC-004Network meta-analysis
Sourceopen_in_newKassab S, Cumming RG, Berkovic D, et al. Effectiveness of fenugreek as a galactagogue. A network meta-analysis. Phytother Res. 2018;32(3):402-412. doi:10.1007/s12668-017-0431-z. PMID:29193352.
Population: Lactating women enrolled in randomized trials of fenugreek and other galactagogues.
Dose protocol: Mixed lactation protocols and preparations
Key findings: Suggested increased milk volume, but with small and heterogeneous supporting trials.
Notes: Enough for low-confidence galactagogue framing only.
Paper content
This network meta-analysis suggests fenugreek may increase milk volume, but the underlying trials are small, methodologically uneven, and use mixed preparations. It is enough to keep fenugreek in the conversation as a possible galactagogue, but not enough to frame it as a dependable lactation intervention for everyone.
fg-SRC-005Triple-blind randomized controlled trial.
Sourceopen_in_newRouhi M, Hossieni MB, Khodaie L, Mohammad-Alizadeh-Charandabi S, Mirghafourvand M. Investigating the Effectiveness of Fenugreek on the Quantity of Breast Milk and the Level of Prolactin in Mothers of Preterm Newborns: A Randomized Controlled Clinical Trial. Curr Drug Res Rev. 2025;17(3):471-480. doi:10.2174/0125899775313919240822102906. PMID:41239794.
Population: Mothers with preterm newborns less than 32 weeks gestation.
Dose protocol: 500 mg fenugreek capsule three times daily for 10 days in mothers of preterm infants
Key findings: Fenugreek increased milk volume versus placebo. Prolactin levels did not differ, suggesting a non-prolactin-mediated mechanism.
Notes: Triple-blind RCT with good design quality. Specific to preterm mothers.
Paper content
This triple-blind RCT tested fenugreek capsules (~500 mg three times daily) versus placebo in 68 mothers of preterm newborns from postpartum day 5 to day 14. Fenugreek increased milk volume compared to placebo, but prolactin levels did not differ significantly between groups, suggesting the galactagogue effect may operate through mechanisms other than prolactin elevation. The study provides targeted evidence for fenugreek in a specific population (preterm mothers) and adds to the lactation evidence base with a well-controlled design.
fg-SRC-006Scoping review.
Sourceopen_in_newAmiri Ardekani E, Parvizi MM, Zare R, Mosaffa Jahromi M, Rampp T, Pasalar M. Exploring the Adverse Effects of Fenugreek in Humans: A Scoping Review. Iran J Med Sci. 2026;51(1):4-18. doi:10.30476/ijms.2025.106073.4017. PMID:41625343.
Population: Human studies from January 1990 to September 2024.
Dose protocol: Scoping review of 60 human studies (1990 to 2024) on fenugreek adverse effects
Key findings: Mild GI discomfort is the most common adverse effect. Hypoglycemia, allergic reactions, and drug interactions also reported. No fatalities.
Notes: Best current safety-focused human review for fenugreek.
Paper content
This scoping review analyzed 60 human studies published from 1990 to 2024 to characterize the adverse effect profile of fenugreek. Mild gastrointestinal discomfort was the most commonly reported side effect of oral consumption. Other reported effects included hypoglycemia, allergic reactions, and medication interactions. Most adverse effects were mild and self-resolving. No fatalities were reported. The review supports the general safety of fenugreek supplementation while reinforcing caution around glucose-lowering interactions and allergy risk.